Add-on azithromycin reduces sputum cytokines in non-eosinophilic asthma: an AMAZES substudy.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 33414242.
- Also identified by DOI 10.1136/thoraxjnl-2020-216331.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Add-on azithromycin (AZM) significantly reduces exacerbations in poorly controlled asthma irrespective of disease phenotype. In a predefined substudy of the original AMAZES protocol (500 mg, three times a week for 48 weeks), we report that AZM treatment reduces key sputum inflammatory proteins (interleukin (IL)-6, IL-1β and extracellular DNA), which is more evident in non-eosinophilic asthma (NEA). Moreover, AZM reduced <i>Haemophilus influenzae</i> load only in NEA. Our data support the anti-inflammatory effects of AZM in poorly controlled asthma. Prospective studies are required to identify patients that derive greatest benefit from AZM add-on therapy.
Medical subject headings
- Asthma
- Azithromycin
- Cytokines
- Sputum